<!DOCTYPE HTML>
<!--
	Future Imperfect by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
	<head>
		<title>S.C.A.B.P - The Rigorous Testing of Vaccines Before Commercial Use</title>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
		<link rel="stylesheet" href="../assets/css/main.css" />
	</head>
	<body class="is-preload">

		<!-- Wrapper -->
			<div id="wrapper">

				<!-- Header -->
				<header id="header">
					<h1><a href="../index.html">S.C.A.B.P</a></h1>
					<nav class="links">
						<ul>
							<li><a href="../index.html">Home</a></li>
							<li><a href="../statistics.html">Statistics</a></li>
							<li><a style="color: #2ebaae;" href="../chemistry.html">Chemistry</a></li>
							<li><a href="../astronomy.html">Astronomy</a></li>
							<li><a href="../biology.html">Biology</a></li>
							<li><a href="../psychology.html">Psychology</a></li>
							<li><a href="../about.html">About</a></li>
						</ul>
					</nav>
					<nav class="main">
						<ul>
							<li class="search">
								<a class="fa-search" href="#search">Search</a>
								<form id="search" method="get" action="#">
									<input type="text" name="query" placeholder="Search" />
								</form>
							</li>
							<li class="menu">
								<a class="fa-bars" href="#menu">Menu</a>
							</li>
						</ul>
					</nav>
				</header>

				<!-- Menu -->
					<section id="menu">

						<!-- Search -->
							<section>
								<form class="search" method="get" action="#">
									<input type="text" name="query" placeholder="Search" />
								</form>
							</section>


					</section>

				<!-- Main -->

				<div>
					<section id="comment-section">

						<header>
							<h3>
								Comment Section
							</h3>
						</header>
		
						<ul class="comment-list"> 
							<li class="comment">
		
								<div class="vcard bio">
									<img src="../images/avatars/female_comment.png" alt="Image placeholder">
								</div>
		
								<div class="comment-body">
									<h3>Rebecca Taillieu</h3>
									<div class="meta mb-3">March 3, 2021 at 2:21pm</div>
									<p>Wow! What an interesting topic!</p>
									<p><a href="#" class="reply">Reply</a></p>
								</div>
		
								<ul class="children">
									<li class="comment">
		
										<div class="vcard bio">
										<img src="../images/avatars/avatarjeroen.jpg" alt="Image placeholder">
										</div>
										<div class="comment-body">
										<h3>Jeroen Lardot</h3>
										<div class="meta mb-3">March 3, 2021 at 3:43pm</div>
										<p>Definitely agree!</p>
										<p><a href="#" class="reply">Reply</a></p>
										</div>
									</li>
								</ul>
							</li>

							<li class="comment">
		
								<div class="vcard bio">
									<img src="../images/avatars/avatarchenjian.jpg" alt="Image placeholder">
								</div>
		
								<div class="comment-body">
									<h3>Chenjian Wang</h3>
									<div class="meta mb-3">March 3, 2021 at 3:21pm</div>
									<p>Random comment</p>
									<p><a href="#" class="reply">Reply</a></p>
								</div>
							</li>
						</ul>
		
						<div class="comment-form-wrap">
		
							<h3 class="mb-5">Leave a comment</h3>
		
							<form action="#">
		
								<div class="form-group">
									<label for="name">Name *</label>
									<input type="text" class="form-control" id="name">
								</div>
		
								<div class="form-group">
									<label for="message">Message</label>
									<textarea name="" id="message" cols="30" rows="5" class="form-control"></textarea>
								</div>
		
								<div class="form-group">
									<input type="submit" value="Post Comment" class="btn py-3 px-4 btn-primary">
								</div>
								</form>
						</div>
				</section>
			</div>


					<div id="main">

						<!-- Post -->
							<article class="post">
								<header>
									<div class="title">
										<h2><a href="#">The Rigorous Testing of Vaccines Before Commercial Use</a></h2>
										<p>An insight into the details of the COVID-19 vaccine development</p>
									</div>
									<div class="meta">
										<time class="published" datetime="2015-11-01">March 19, 2021</time>
										<a href="../about.html" class="author"><span class="name">Jieh-Jang Chen</span><img src="../images/avatars/avatarjiehjang.jpg" alt="" /></a>
										<a class="author"><span class="name">ARTICLE</span><img src="https://img.icons8.com/carbon-copy/100/000000/literature.png" alt="" /></a>
									</div>
								</header>

								<span class="image presented"><img src="../images/headliners/covid2.jpg" alt="" />
								</span>
								<p>In many parts of the world, including Belgium, vaccines have been slowly rolling out to the public. Many people might still have doubts and concerns about the vaccines. This is completely reasonable, as nobody would want to inject something they do not know or understand in their body. By gaining more knowledge on what vaccines are, how they work, how they are tested and produced will help everyone make a more educated opinion on vaccines, as the choose is still up to you.</p>

								<table style="width: 40%; border-collapse: collapse; margin: 0px auto;">
									<tbody>
										<tr>
											<td style="width: 100%; text-align: left;">BNT162b1 is a lipid-nanoparticle-formulated, nucleoside-modified mRNA vaccine, that encodes the trimerized receptor-binding domain (RBD) of the spike glycoprotein of SARS-CoV-2.<br></td>
										</tr>
									</tbody>
								</table>
								<p></p>
								<p>RBD-binding IgG concentrations and SARS-CoV-2-neutralizing titres was compared with covid-19 infected patients to assess immunogenicity. After the first dose, geometric mean concentration (GMCs) was similar in the 30-&mu;g and 100-&mu;g groups and higher than the corona patients after the second dose, with 10 &mu;g or 30 &mu;g BNT162b1, the RBD-binding IgG GMCs were around 8.0&ndash;50-fold that of the GMC of the convalescent serum panel (sample from the corona patients). For SARS-CoV-2-neutralizing geometric mean titres (GMTs) would increase to 1.8-fold and 2.8-fold compared to corona patients after second dose of 10 &mu;g and 30 &mu;g and continue to increase to 1.9-fold and 4.6-fold compared to corona patients after 35 days (14 days after second dose). The result show that BNT162b1 has great potential of the vaccine to provide protection however the efficacy of the vaccine needs further testing. Experiments also show that no substantial differences in immunogenicity between the 30-&mu;g and 100-&mu;g dose levels after the first dose. Which suggest best dose level maybe between10 &mu;g and 30 &mu;g.</p>
								<p>As previously mentioned, this is only a portion of several long and extensive investigations on how the vaccines are tested before officially administered and incensed for commercial use. Other tests such as effect on elders or children, efficacy and durability of the vaccine is required. This can be considered a first step of many. Be sure to stay tuned on other article relating to SARS-CoV-2 and its vaccines.</p>
										
							<footer>
								<ul class="stats">
									<li><a href="#">Chemistry</a></li>
										<li><a href="#" class="icon solid fa-heart">28</a></li>
										<li><a href="#" class="icon solid fa-comment">128</a></li>
									</ul>
								</footer>
							</article>
					</div>
			</div>


			





			
		<!-- Scripts -->
			<script src="../assets/js/jquery.min.js"></script>
			<script src="../assets/js/browser.min.js"></script>
			<script src="../assets/js/breakpoints.min.js"></script>
			<script src="../assets/js/util.js"></script>
			<script src="../assets/js/main.js"></script>	
			<script src="../assets/js/audio.js"></script>
			<script src="../assets/js/test.js"></script>

	</body>
</html>